US 12,358,970 B2
Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
Andrew M. Scharenberg, Seattle, WA (US)
Assigned to Seattle Children's Hospital, Seattle, WA (US)
Filed by Seattle Children's Hospital, Seattle, WA (US)
Filed on Aug. 8, 2023, as Appl. No. 18/446,018.
Application 18/446,018 is a continuation of application No. 16/467,013, granted, now 11,753,460, previously published as PCT/US2017/065746, filed on Dec. 12, 2017.
Claims priority of provisional application 62/433,540, filed on Dec. 13, 2016.
Prior Publication US 2024/0117008 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/62 (2006.01); C07K 14/71 (2006.01); C07K 14/715 (2006.01); C12N 15/63 (2006.01)
CPC C07K 14/7155 (2013.01) [C12N 15/62 (2013.01); C07K 2317/53 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01)] 20 Claims
 
1. A method for making a genetically modified cell, comprising contacting a cell with:
(i) a first nucleic acid encoding a first chemically inducible signaling complex (CISC) component, wherein the first CISC component comprises in an N-to-C terminal order:
(a) an extracellular domain comprising an FK506-binding protein (FKBP) domain;
(b) an IL-2 receptor γ (IL-2Rγ) transmembrane domain; and
(c) an IL-2Ry cytoplasmic signaling domain; and
(ii) a second nucleic acid encoding a second CISC component, wherein the second CISC component comprises in an N-to-C-terminal order:
(a) an extracellular domain comprising an FKBP-rapamycin-binding (FRB) domain;
(b) an IL-2 receptor β (IL-2RB) transmembrane domain; and
(c) an IL-2Rβ cytoplasmic signaling domain.